Expression of S100A4 in Invasive Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm of the Pancreas.
- Author:
Hyoun Jong MOON
1
;
Ji Yeong AN
;
Weon Young CHANG
;
Kee Tack JANG
;
Jin Seok HEO
;
Seong Ho CHOI
;
Yong Il KIM
Author Information
1. Department of Surgery, Kwandong University College of Medicine, Korea.
- Publication Type:Original Article
- Keywords:
Carcinoma, Pancreatic Ductal;
Intraductal Papillary Mucinous Neoplasm, Pancreatic;
Tumor Markers, Biological;
S100A4;
Immunohistochemistry
- MeSH:
Adenocarcinoma*;
Carcinoma, Pancreatic Ductal;
Cystadenoma, Serous;
Humans;
Immunohistochemistry;
Mucins*;
Neuroendocrine Tumors;
Pancreas*;
Pancreatic Ducts;
Pancreatitis, Chronic;
Biomarkers, Tumor
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2004;8(2):92-97
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: A pancreatic ductal adenocarcinoma is one of the most fatal cancers, as the majority of the patients present with locally advanced or metastatic tumors in the late stages of the disease. However, there is no simple, sensitive, noninvasive, and inexpensive test for the early detection of pancreatic ductal adenocarcinomas. In recent studies, S100A4 has emerged as an important protein in the tumorgenesis of pancreatic adenocarcinomas. METHODS: The possibility of the expression of S100A4 as a new tumor marker of pancreatic adenocarcinomas was confirmed using immunohistochemistry to 32-pancreatic ductal adenocarcinomas, 20 IPMN (intraductal papillary mucinous neoplasm), 8 serous cystadenomas, 5 chronic pancreatitis and 3 neuroendocrine tumors. RESULTS: Thirty-one (96.9%) ductal adenocarcinoma cases and 11 (55.5%) IPMN expressed S100A4, whereas all normal pancreatic tissues (47 cases), chronic pancreatitis and endocrine tumors did not. The expression of S100A4 was associated with the degree of dysplasia in IPMN, but not with the differentiation of ductal adenocarcinomas. CONCLUSION: The overexpression of S100A4 in adenocarcinomas and early emerging IPMN may suggest its potential as a diagnostic marker for the early detection of pancreatic ductal adenocarcinomas.
